Effect of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present clinical study is to evaluate the efficacy and safety of the DA-5515 (Circulan Soft Cap.) in patients with chronic fatigue symptoms due to impaired blood circulation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A Pharmaceutical

Criteria

Inclusion Criteria:

• Rutherford's category 0/0 or Ⅰ/1

• ABI <1.0

• CIS greater than 76

• HADS less than or equal to 10

• Subjects who have fatigue symptoms more than 1 month

Exclusion Criteria:

• Subjects who have diseases that can cause fatigue

• Subjects who are taking medication that can cause fatigue